Compound 977
Identifiers
- Canonical SMILES:
CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1S(=O)(=O)C(F)(F)F)S(=O)(=O)Nc1ncnc2CN(CCc12)C1CCN(CC2=C(CCC(C)(C)C2)c2ccc(Cl)cc2)CC1
- IUPAC name:
N-[7-[1-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperidin-4-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-4-[[(2R)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)benzenesulfonamide
- InChi:
InChI=1S/C46H57ClF3N7O4S3/c1-45(2)21-16-39(32-10-12-34(47)13-11-32)33(27-45)28-56-23-18-36(19-24-56)57-25-20-40-42(29-57)51-31-52-44(40)54-64(60,61)38-14-15-41(43(26-38)63(58,59)46(48,49)50)53-35(17-22-55(3)4)30-62-37-8-6-5-7-9-37/h5-15,26,31,35-36,53H,16-25,27-30H2,1-4H3,(H,51,52,54)/t35-/m1/s1
- InChiKey:
FRJIPSUXXYFZOO-PGUFJCEWSA-N
External links
51042007 |
External search
Bibliography (1)
Publication | Name |
---|---|
Karen Miller-Moslin, Bakary-Barry Toure, Michael Scott Visser, Naeem Yusuff, Novartis Ag. . Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer None. | 10 |
Pharmacological data
Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|
1 | 0 | 0 | 0 |
Targets
PPI family | Best activity | Diseases | MMoA |
---|---|---|---|
BCL2-Like / BAX | 7.51 | cancer | Inhibition |
Physicochemical filters
Descriptor | Lipinski's RO5 | Veber | Pfizer's 3/75 | |
---|---|---|---|---|
Compliance | ||||
MW | 959.33 g/mol | |||
HBA | 11 | |||
HBD | 2 | |||
HBA + HBD | 13 | |||
AlogP | 7.25 | |||
TPSA | 127.84 | |||
RB | 16 |
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources | Biochemical tests | Cellular tests | PK tests | Cytotoxicity tests |
---|---|---|---|---|
1 | 1 | 0 | 0 | 0 |
Pharmacological data
Bibliography | Name | Target | Competition | Assay type | Assay name | Cell line | Activity type | Activity |
---|---|---|---|---|---|---|---|---|
WO2011029842 | 10 | BCL2 P10415 |
|
Biochemical assay | Surface Plasmon Resonance | pIC50 (half maximal inhibitory concentration, -log10) | 7.51 |
Ta | Structure | Name | Drugbank ID |
---|---|---|---|
0.6230 | Navitoclax | DB12340 | |
0.4278 | Venetoclax | DB11581 | |
0.3795 | (3Z)-N,N-DIMETHYL-2-OXO-3-(4,5,6,7-TETRAHYDRO-1H-INDOL-2-YLMETHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE | DB08039 | |
0.3768 | Presatovir | DB12165 | |
0.3631 | (4aS)-5-[(2,4-diaminopteridin-6-yl)methyl]-4a,5-dihydro-2H-dibenzo[b,f]azepin-8-ol | DB08448 | |
0.3614 | Vintafolide | DB05168 | |
0.3611 | Quinupristin | DB01369 | |
0.3600 | Cyclothiazide | DB00606 | |
0.3575 | Henatinib | DB13019 | |
0.3560 | 2-[({2-[(1Z)-3-(DIMETHYLAMINO)PROP-1-ENYL]-4-FLUOROPHENYL}SULFONYL)AMINO]-5,6,7,8-TETRAHYDRONAPHTHALENE-1-CARBOXYLIC ACID | DB07323 | |
0.3538 | GDC-0349 | DB13072 | |
0.3533 | N-{2-[6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2,2-DIMETHYL-3-OXO-2,3-DIHYDRO-4H-1,4-BENZOTHIAZIN-4-YL]ETHYL}ACETAMIDE | DB06899 | |
0.3518 | Sulfaisodimidine | DB13283 | |
0.3516 | Tianeptine | DB09289 | |
0.3465 | SU-11652 | DB08009 |